Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 7Colorectal Neoplasms 6Stomach Neoplasms 4Biliary Tract Neoplasms 4Esophageal Neoplasms 3Neoplasms 2Gallbladder Neoplasms 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Muscle Invasive Bladder Cancer (MIBC) 1Metastatic HER2-positive Breast Cancer 1Hemangiosarcoma 1Head and Neck Neoplasms 1HER2-expressing Cancers 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Advanced Malignancies 1

Interventions

Oxaliplatin 64pembrolizumab 48Fluorouracil 44Capecitabine 38Nivolumab 33Leucovorin 32Paclitaxel 28Trastuzumab 19Docetaxel 18Cisplatin 18S 1 (combination) 16Bevacizumab 15Ramucirumab 13Irinotecan 13Drug Therapy 13tislelizumab 12Cyclophosphamide 12fludarabine 10Carboplatin 10Radiotherapy 9Magnetic Resonance Spectroscopy 9trastuzumab deruxtecan 8sintilimab 8Specimen Handling 8Biopsy 8atezolizumab 7Surgical Procedures, Operative 7Gemcitabine 7zolbetuximab 6durvalumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Stomach Neoplasms × zanidatamab × 1 year × Clear all
NCT05152147 2026-05-19

HERIZON-GEA-01

Jazz Pharmaceuticals

Phase 3 Active not recruiting
920 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Jazz Pharmaceuticals

Phase 2 Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07176312 2026-02-04

ZANGEA

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Recruiting
80 enrolled
Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Jazz Pharmaceuticals

Phase 2 Completed
74 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡